IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0614648
(2003-07-07)
|
등록번호 |
US-8119121
(2012-02-21)
|
발명자
/ 주소 |
- Fraser, John K.
- Hedrick, Marc H.
|
출원인 / 주소 |
- Cytori Therapeutics, Inc.
|
대리인 / 주소 |
Knobbe Martens Olson & Bear LLP
|
인용정보 |
피인용 횟수 :
36 인용 특허 :
71 |
초록
▼
Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cel
Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
대표청구항
▼
1. An autologous adipose tissue implant comprising: a first portion of intact (non-disaggregated) adipose tissue removed from a patient mixed with a concentrated population of adipose-derived cells that comprises stem cells,wherein the population of adipose-derived cells comprising stem cells is con
1. An autologous adipose tissue implant comprising: a first portion of intact (non-disaggregated) adipose tissue removed from a patient mixed with a concentrated population of adipose-derived cells that comprises stem cells,wherein the population of adipose-derived cells comprising stem cells is concentrated from a second portion of adipose tissue removed from the same patient, andwherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 1.7×105 cells/ml. 2. The autologous adipose tissue implant of claim 1, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.1×105 cells/ml. 3. The autologous adipose tissue implant of claim 1, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.5×105 cells/ml. 4. The adipose tissue implant of claim 1, further comprising an additive. 5. The adipose tissue implant of claim 4, wherein said additive is selected from the group consisting of growth factors, cytokines, a preformed matrix, cells, tissue, tissue fragments, disaggregating agents, antimicrobial agents, scaffolds, immunosuppressive agents, and antibiotics, or any combination thereof. 6. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is not cultured. 7. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is cultured. 8. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is isolated in a closed, sterile fluid/tissue pathway. 9. The adipose tissue implant of claim 1, wherein the first, second, or both portions are cryopreserved after removal from the patient. 10. An autologous adipose tissue implant, comprising: a first portion of intact (non-disaggregated) adipose tissue comprising connective tissue removed from a patient, mixed with a concentrated population of adipose-derived cells that comprises stem cells, wherein the population of adipose-derived cells comprising stem cells is concentrated from a second portion of adipose tissue that is removed from the same patient and enzymatically treated, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 1.7×105 cells/ml. 11. The autologous adipose tissue implant of claim 10, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.1×105 cells/ml. 12. The autologous adipose tissue implant of claim 10, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.5×105 cells/ml. 13. The adipose tissue implant of claim 10, further comprising an additive. 14. The adipose tissue implant of claim 13, wherein said additive is selected from the group consisting of growth factors, cytokines, a preformed matrix, cells, tissue, tissue fragments, disaggregating agents, antimicrobial agents, scaffolds, immunosuppressive agents, and antibiotics, or any combination thereof. 15. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is not cultured. 16. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is cultured. 17. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is isolated in a closed, sterile fluid/tissue pathway. 18. The adipose tissue implant of claim 10, wherein the first, second, or both portions are cryopreserved after removal from the patient.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.